RetroSense Therapeutics raises $6 mln in Series B funding
RetroSense Therapeutics raised $6 million in Series B funding to continue its goal of using gene therapy and optogenetics to restore vision. Investors in the funding round included existing investors BlueWater Angels and new investors RBV Capital, ExSight Capital and Santen Pharmaceutical Co. Earlier this year, RetroSense closed a $7 million Series A funding round, bringing total capital raised to $13 million. As part of the funding, Dmitry Kuzmin of RBV Capital, joined the RetroSense's board.
13 November 2015•3 mins read
